RELMADA THERAPEUTICS, INC. — Director's Dealing 2020

Jul 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2020-07-01

Reporting Person: CASAMENTO CHARLES J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-01	Common Stock	S	3000	$43.8924	Disposed	37000	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	21484	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2020. The range of prices for the transaction reported on this line was $43.03 to $44.63. The average weighted price was $43.8924. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F2: Represents shares of common stock held by a family trust. Mr. Casamento disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the filing of this report is not an admission that Mr. Casamento is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934, or for any other purpose.